Producer
Hubei Biocause Pharmaceutical Co., Ltd.
Chinese specialty pharmaceutical chemical company (HQ Jingmen, Hubei; listed on Shanghai Stock Exchange); one of China's largest ibuprofen API producers, producing both ibuprofen and related NSAIDs (naproxen, ketoprofen) for domestic and export markets. Hubei Biocause's ibuprofen production contributes to China's dominant position in global ibuprofen API supply — which accounts for 90-95% of US/EU ibuprofen imports by volume. China's ibuprofen cost advantage stems from integrated petrochemical-pharmaceutical supply chains (isobutylbenzene, the key ibuprofen raw material, is a petroleum derivative produced cheaply in Chinese integrated chemical complexes).
1
Inputs supplied
1
Goods downstream
0
Facilities
0
Stories
What they make
1 input Hubei Biocause Pharmaceutical Co., Ltd. supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Hubei Biocause Pharmaceutical Co., Ltd. makes — pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Ibuprofen API
65%Other NSAID APIs
25%Pharmaceutical Intermediates
10%
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Chokepoint2021
China's ibuprofen API market — anchored by producers including Hubei Biocause, CSPC, and Xinhua Pharmaceutical — supplies an estimated 90-95% of global ibuprofen imports by volume. The US has no domestic ibuprofen API production capacity; every Advil, Motrin, and store-brand ibuprofen tablet sold at US pharmacies begins its synthesis in a Chinese facility. This concentration was specifically flagged by the FDA, DoD, and Congressional reports on pharmaceutical supply chain resilience following COVID-19. Hubei Biocause alone accounts for a substantial fraction of that Chinese supply — making a Jingmen, Hubei facility a material determinant of whether American consumers can obtain the world's most common OTC pain reliever if US-China relations deteriorate to the point of export restriction. The same geopolitical tension that affects semiconductor chips or rare earth exports could, in a conflict scenario, affect the supply of the ibuprofen in a medicine cabinet.
IQVIA Institute ↗Origin2023
Hubei Biocause Pharmaceutical is based in Jingmen, Hubei Province — a secondary Chinese city located 200km northwest of Wuhan, in a region whose economy is anchored by Sinopec's Jingmen petrochemical complex (one of China's early petroleum refining centers built in the 1970s). Biocause's ibuprofen synthesis uses isobutylbenzene (IBB) as its key raw material — IBB is a petroleum derivative produced by alkylation of benzene (from oil refining) with isobutylene (from cracking). The proximity to Jingmen Sinopec's petroleum processing infrastructure gives Biocause integrated access to cheap IBB feedstock, making Chinese ibuprofen structurally cost-advantaged versus Western producers who must source IBB on global spot markets. Hubei Biocause was established in the 1990s-2000s as the Jingmen chemical cluster matured from pure petroleum refining into pharmaceutical chemical manufacturing.
Hubei Biocause Pharmaceutical Co., Ltd. ↗